State of Alaska Department of Revenue Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

State of Alaska Department of Revenue boosted its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 17.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,074 shares of the company’s stock after purchasing an additional 2,766 shares during the period. State of Alaska Department of Revenue owned about 0.06% of TransMedics Group worth $1,189,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Harbour Capital Advisors LLC lifted its holdings in TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after purchasing an additional 81 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in TransMedics Group by 33.7% during the 3rd quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after purchasing an additional 219 shares in the last quarter. National Bank of Canada FI lifted its holdings in TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares in the last quarter. Quarry LP lifted its holdings in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock worth $76,000 after purchasing an additional 316 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TMDX shares. Piper Sandler dropped their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a report on Tuesday, December 3rd. Robert W. Baird lowered their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, December 11th. Finally, TD Cowen lowered their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

TMDX opened at $69.52 on Thursday. The stock’s 50 day simple moving average is $65.75 and its 200 day simple moving average is $107.98. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The firm has a market cap of $2.33 billion, a price-to-earnings ratio of 73.96 and a beta of 2.12.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.